AzTrials
AzTrials

ESA-naive Hemodialysis Chronic Kidney Disease Patients With AnemiaPhase 3NCT02780141

A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

A Phase 3 study testing roxadustat in people with ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia, run by Astellas Pharma Inc at 47 sites in Japan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to evaluate the safety and efficacy of ASP1517 in ESA-naive hemodialysis chronic kidney disease patients with anemia. Read more about this study

Who is it for?
Ages 20 years and older
What is being tested?
roxadustat
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
75 participants
Where
47 sitesJapan
Study dates
2 Jun 2016to 12 Dec 2017
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Mean of the subjects' two most recent Hb values during the Screening Period must be ≤10.0 g/dL with an absolute difference ≤1.0 g/dL between the two values
  • Either transferrin saturation (TSAT) ≥ 5% or serum ferritin ≥ 30 ng/mL during the screening period
  • Female subject must either:
  • Be of non-childbearing potential:
  • post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
  • documented surgically sterile Or, if of childbearing potential,
Show all 13Show fewer
  • Agree not to try to become pregnant during the study and for 28 days after the final study drug administration
  • And have a negative pregnancy test at Screening
  • And, if heterosexually active, agree to consistently use two forms of highly effective form of birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and continued for 28 days after the final study drug administration.
  • Female subject must agree not to breastfeed starting at Screening and throughout the study period, and continued for 28 days after the final study drug administration.
  • Female subject must not donate ova starting at Screening and throughout the study period, and continued for 28 days after the final study drug administration.
  • Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective form of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 12 weeks after the final study drug administration
  • Male subject must not donate sperm starting at Screening and throughout the study period and, for 12 weeks after the final study drug administration

Who cannot join

  • Concurrent retinal neovascular lesion requiring treatment and macular edema requiring treatment
  • Concurrent autoimmune disease with inflammation that could impact erythropoiesis
  • History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastroparesis
  • Uncontrolled hypertension
  • Concurrent congestive heart failure (NYHA Class III or higher)
  • History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the screening assessment
Show all 16Show fewer
  • Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibody at the screening assessment, or positive for human immunodeficiency virus (HIV) in a past test
  • Concurrent other form of anemia than renal anemia
  • Having received treatment with protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the screening assessment
  • Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), or total bilirubin that is greater than the criteria, or previous or concurrent another serious liver disease at screening assessment
  • Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)
  • Having undergone blood transfusion and/or a surgical procedure considered to promote anemia (excluding shunt reconstruction surgery for access to the blood) within 4 weeks before the screening assessment
  • Having undergone a kidney transplantation
  • Having a previous history of treatment with ASP1517.
  • History of serious drug allergy including anaphylactic shock
  • Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before informed consent acquisition

Trial locations and contacts

47 sites in 1 country.

47 sites in 1 country

Japan47 sites

  • Site JP00003

    Aichi

  • Site JP00005

    Aichi

  • Site JP00042

    Aichi

  • Site JP00044

    Aichi

  • Site JP00020

    Chiba

  • Site JP00010

    Ehime

  • Site JP00021

    Ehime

  • Site JP00013

    Fukuoka

  • Site JP00011

    Fukushima

  • Site JP00035

    Fukushima

  • Site JP00017

    Gifu

  • Site JP00033

    Gifu

  • Site JP00012

    Gunma

  • Site JP00016

    Gunma

  • Site JP00025

    Gunma

  • Site JP00046

    Hiroshima

  • Site JP00015

    Hokkaido

  • Site JP00023

    Hokkaido

  • Site JP00028

    Hokkaido

  • Site JP00038

    Hokkaido

  • Site JP00040

    Hokkaido

  • Site JP00045

    Hokkaido

  • Site JP00034

    Hyōgo

  • Site JP00008

    Ibaraki

  • Site JP00018

    Ibaraki

  • Site JP00027

    Ibaraki

  • Site JP00030

    Ibaraki

  • Site JP00022

    Ishikawa

  • Site JP00041

    Kagoshima

  • Site JP00031

    Kumamoto

  • Site JP00037

    Kumamoto

  • Site JP00009

    Nagano

  • Site JP00014

    Nagano

  • Site JP00026

    Nagano

  • Site JP00047

    Nagano

  • Site JP00002

    Niigata

  • Site JP00029

    Niigata

  • Site JP00039

    Okayama

  • Site JP00024

    Okinawa

  • Site JP00036

    Osaka

  • Site JP00006

    Saitama

  • Site JP00032

    Shizuoka

  • Site JP00043

    Tokushima

  • Site JP00048

    Tokyo

  • Site JP00007

    Tottori

  • Site JP00019

    Toyama

  • Site JP00004

    Yamaguchi

Other trials in Japan

About this study

Official title: A Phase 3, Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 in Erythropoiesis Stimulating Agent-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

The objective of this study is to evaluate the safety and efficacy of ASP1517 in ESA-naive hemodialysis chronic kidney disease patients with anemia.

Being tested
roxadustat
Keywords
Renal anemia, Roxadustat, ASP1517, Hemodialysis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • roxadustatDrug

    Also called ASP1517

    Oral

Study groups in NCT02780141
Study groupRoleWhat they receive
ASP1517 Low dose GroupExperimentalStudy drug will be dosed three times weekly and dose adjustments will be made during the study.
Receives: Drug: roxadustat
ASP1517 High dose GroupExperimentalStudy drug will be dosed three times weekly and dose adjustments will be made during the study.
Receives: Drug: roxadustat

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hemoglobin (Hb) Response rate

    Hb response is defined as reaching target values for Hb and change of Hb from baseline

    Measured: Up to Week 24

Secondary outcomes (27)

  1. Average Hb level from Week 18 to 24

    Measured: Week 18 to 24

  2. Change from baseline in the average Hb level from Week 18 to 24

    Measured: Baseline and Weeks 18 to 24

  3. Proportion of participants with the target Hb level from Week 18 to 24

    Measured: Week 18 to 24

  4. Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment

    Measured: Up to Week 4

  5. Proportion of measurement points with the target Hb level

    Measured: Up to Week 24

  6. Proportion of participants with the target Hb level at each week

    Measured: Up to Week 24

  7. Proportion of participants with the lower limit of the target Hb level

    Measured: Up to Week 24

  8. Time to achieve the lower limit of the target Hb level

    Measured: Up to Week 24

  9. Change from baseline in Hb levels to each week

    Measured: Baseline and Up to Week 24

  10. Average hematocrit level

    Measured: Up to Week 24

  11. Average reticulocyte level

    Measured: Up to Week 24

  12. Average iron (Fe) level

    Measured: Up to Week 24

  13. Average ferritin level

    Measured: Up to Week 24

  14. Average transferrin level

    Measured: Up to Week 24

  15. Average total iron binding capacity level

    Measured: Up to Week 24

  16. Average soluble transferrin receptor level

    Measured: Up to Week 24

  17. Average transferrin saturation level

    Measured: Up to Week 24

  18. Average reticulocyte hemoglobin content level

    Measured: Up to Week 24

  19. Quality of life assessed by EQ-5D-5L

    EQ-5D-5L: EuroQol 5 Dimension 5 Levels

    Measured: Up to Week 24

  20. Quality of life assessed by FACT-An

    FACT-An: Functional Assessment of Cancer Therapy-Anemia

    Measured: Up to Week 24

  21. Number of hospitalizations

    Measured: Up to Week 24

  22. Duration of hospitalizations

    Measured: Up to Week 24

  23. Safety assessed by incidence of adverse events

    Measured: Up to Week 24

  24. Number of participants with abnormal Laboratory values and/or adverse events related to treatment

    Measured: Up to Week 24

  25. Number of participants with abnormal Vital signs and/or adverse events related to treatment

    Measured: Up to Week 24

  26. Safety assessed by standard 12-lead electrocardiogram

    Measured: Up to Week 24

  27. Plasma concentration of unchanged ASP1517

    Measured: Up to Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 May 2016 (estimated)
  2. Study start2 Jun 2016
  3. Primary completion12 Dec 2017
  4. Study completion12 Dec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
75 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02780141
Sponsor's protocol ID
1517-CL-0308
Status last verified
Oct 2024
First submitted
19 May 2016
Last updated
30 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Publications

  • Hamano T, Yamaguchi Y, Goto K, Mizokawa S, Ito Y, Dellanna F, Barratt J, Akizawa T. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan. Adv Ther. 2024 Apr;41(4):1526-1552. doi: 10.1007/s12325-023-02727-3. Epub 2024 Feb 16.

    PubMed 38363463

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.

    PubMed 36005278

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing roxadustat in people with ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia, run by Astellas Pharma Inc at 47 sites in Japan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 47 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hemoglobin (Hb) Response rate (time frame: Up to Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02780141, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in